Gemphire Therapeutics Inc (NASDAQ:GEMP) saw unusually-strong trading volume on Thursday . Approximately 1,663,094 shares were traded during trading, an increase of 242% from the previous session’s volume of 486,474 shares.The stock last traded at $2.15 and had previously closed at $1.92.

Several analysts have recently weighed in on GEMP shares. Zacks Investment Research upgraded shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Tuesday, August 14th. Canaccord Genuity restated a “buy” rating and set a $6.00 price objective on shares of Gemphire Therapeutics in a research report on Monday, August 13th. Roth Capital raised their price objective on shares of Gemphire Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 27th. Jefferies Financial Group cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 price objective on the stock. in a research report on Monday, August 13th. Finally, Raymond James started coverage on shares of Gemphire Therapeutics in a research report on Wednesday, May 16th. They set an “outperform” rating and a $22.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $17.82.

The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.64 and a current ratio of 4.64. The firm has a market cap of $27.10 million, a P/E ratio of -0.68 and a beta of 1.35.

Gemphire Therapeutics (NASDAQ:GEMP) last released its earnings results on Monday, August 13th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. equities analysts predict that Gemphire Therapeutics Inc will post -1.99 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in GEMP. Segall Bryant & Hamill LLC grew its holdings in shares of Gemphire Therapeutics by 100.0% during the 1st quarter. Segall Bryant & Hamill LLC now owns 30,000 shares of the company’s stock valued at $195,000 after purchasing an additional 15,000 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Gemphire Therapeutics by 63.7% during the 1st quarter. Northern Trust Corp now owns 30,080 shares of the company’s stock valued at $196,000 after purchasing an additional 11,708 shares during the last quarter. JBF Capital Inc. bought a new position in shares of Gemphire Therapeutics during the 2nd quarter valued at $204,000. Acadian Asset Management LLC bought a new position in shares of Gemphire Therapeutics during the 2nd quarter valued at $286,000. Finally, Nomura Holdings Inc. bought a new position in shares of Gemphire Therapeutics during the 2nd quarter valued at $556,000. 32.60% of the stock is currently owned by institutional investors.

Gemphire Therapeutics Company Profile (NASDAQ:GEMP)

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Featured Article: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.